Show simple item record

dc.creatorMorales Munera,Olga Lucía 
dc.creatorPedraza,Angela María 
dc.creatorNiño Serna,Laura Fernanda 
dc.date.accessioned2020-08-06T16:24:08Z
dc.date.available2020-08-06T16:24:08Z
dc.date.created2016-04
dc.identifier.issnISSN: 8755-6863
dc.identifier.issnEISSN: 1099-0496
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/26486
dc.description.abstractObjective: To describe the clinical characteristics of pediatric patients aged6 to 17 years diagnosed with moderate to severe allergic asthma undergoingtreatment with omalizumab (OMB) from January 2007 to February 2014 in6 cities in Colombia. Methods: This retrospective, longitudinal cohort studyincluded 63 children and adolescents. Evaluated outcomes includedsymptoms control, exacerbations frequency, decreased use of asthmacontrol drugs and presence of adverse events before starting treatment andafter 4 and 12 months of OMB use. Results: after 4 and 12 months oftreatment 89% and 96.6% of children under 12 years of age (p ¼ 0.0015) and78% and 91.6% of children over 12 years of age (p ¼ 0.0145) had goodsymptom control, respectively. Furthermore, after 12 months, the number ofexacerbations decreased to 2 (p ¼ 0.00), the frequency of beta2 rescueinhaler use decreased to 0.37 days (p ¼ 0.00), and the use of controller drugsdecreased in 73% of patients, including decreased use of inhaledcorticosteroids in 62%. Only one severe adverse event was reported inone patient. Conclusion: OMB is an effective drug for the clinical control ofmoderate and severe allergic asthma. It reduces asthma symptoms andexacerbations and exhibits good tolerance and few severe adverse event
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.relation.ispartofPediatric Pulmonology, ISSN: 8755-6863,Vol.51, No.S42 (2016-04); pp.s7-s64
dc.relation.ispartofXI SOLANEP International Congress / XV Cystic Fibrosis Latinamerican Congress / XV Brazilian Congress of Pediatric Pulmonology
dc.relation.urihttps://onlinelibrary.wiley.com/doi/epdf/10.1002/ppul.23409
dc.sourcePediatric Pulmonology
dc.titleClinical Course of Asthma of Children Treatedwith Omalizumab: Multicenter Study Colombia
dc.typeconferenceObject
dc.publisherJhon Wiley & Sons
dc.subject.keywordMedical and Health Sciences
dc.subject.keywordPaediatrics and Reproductive Medicine
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.type.spaDocumento de conferencia
dc.rights.accesoAbierto (Texto Completo)
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.identifier.doihttps://doi.org/10.1002/ppul.23409
dc.title.TranslatedTitleCurso clínico de asma de niños tratados con Omalizumab: estudio multicéntrico Colombia
dc.relation.citationEndPages64
dc.relation.citationIssueNo. S42
dc.relation.citationStartPages7
dc.relation.citationTitlePediatric Pulmonology
dc.relation.citationVolumeVol. 51


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record